Tolo Harbour is committed to providing innovative solutions for the in vitro diagnostics industry!

The company discovered for the first time that the CRISPR-Cas12 protein has efficient "trans cleavage activity" and developed the "Holmes/Cas12" enzyme based on the unique advantages of this enzyme.HOLMES"Rapid nucleic acid detection platform technology (one-HOur Low-cost Multipurpose highly Efficient System). Compared with traditional molecular diagnostic technologies, CRISPR-based HOLMES technology has the advantages of high sensitivity, high specificity, rapidity and convenience. This kind of technology has therefore been recognized by the USScienceIt has been hailed as the "next-generation molecular diagnostic technology" by the Journal of Molecular Biology, and has great potential for applications in pathogenic bacteria detection, genetic disease screening, and precision medicine.

The company owns a methodological patent for Cas12 nucleic acid detection (Chinese invention patent, Patent No. ZL201710573752.0) and has obtained the exclusive license for Cas13 diagnostic technology in Greater China (including Hong Kong, Macau and Taiwan) through a "cross-license" with Sherlock Biosciences, Inc. We have obtained the exclusive license of Cas13 diagnostic technology in Greater China (including Hong Kong, Macau and Taiwan) through a "cross-license" with Sherlock Biosciences.

The company is now actively promoting the application of SHERLOCK and HOLMES platform technologies in molecular POCT, clinical infection detection, early tumor screening and concomitant diagnosis, home testing, etc. We are willing to join hands with our in vitro diagnostic counterparts to promote the rapid development of CRISPR diagnostic industry.